NAFLD or NASH

NAFLD or NASH research

You're seeing the 'logged out' version of this page

To access the Sano NAFLD or NASH survey and see if you are eligible for current research, please

Login
or
Sign Up

MAESTRO Clinical Trial

NAFLD or NASH research

9 days remaining

  • Referral study
  • Ethically approved
  • Study site visit necessary
  • Commercial study
  • Sponsored
  • Data transferred outside Sano
  • Clinical Trial
Might be relevant for you

Insights & Information

NAFLD or NASH Prevalence

NAFLD affects approximately 1 in 4 people on a global scale.

NAFLD is highly prevalent on a global scale, but the highest rates are reported in South America and the Middle East, followed by Asia, the USA and Europe. [1]

Genetics

Genetically, NAFLD is complex, although it does have a consistent association with one gene PNPLA3, in European populations. Researchers are calling for further studies to investigate the genetics of NAFLD in diverse populations. [2]

The heritability of NAFLD or NASH is medium - 20% - 70% [3]

Main Symptoms

aching pain in the top right of the tummy
extreme tiredness
unexplained weight-loss
weakness

Early stage NAFLD is usually symptom-less and will only become apparent if diagnosed during tests carried out for another reason. Patients with NASH (a more advanced form of NAFLD) can sometimes experience the above symptoms. [4]

Impacts

Development of NAFLD is closely linked to lifestyle factors, including poor diet and lack of regular exercise. There is currently no drug therapy available for treatment of NAFLD. [5]

It’s estimated that the more advanced form of NAFLD, NASH, will be the most common reason for liver transplants in the USA by 2030. [6]

Resources for advice

These are the best resources we've found so far on managing and learning about NAFLD or NASH . Please let us know if you have other and we'll add them to the list!

Share this page to help us reach more people, build a better information set, and move research forward!